Virtual Library

WS03.03 - Introduction to the IASLC - Why You Should Be a Member

08:06 - 08:21  |  Author(s): Karen Kelly

WS03.04 - Making the Most of WCLC: A Guide for First Time Attendees

08:21 - 08:36  |  Author(s): Jarushka Naidoo

WS03.05 - Planning a Career in Lung Cancer - Bench to Bedside and Educational

08:36 - 08:51  |  Author(s): Anne-Marie Dingemans

WS03.06 - Planning a Career in Lung Cancer - Sponsored and Academic Trials

08:51 - 09:06  |  Author(s): Ross Soo

WS03.07 - Planning a Career in Lung Cancer - A New Era of Trial Designs

09:06 - 09:21  |  Author(s): Simon Ekman

WS03.09 - Principles to Get Your Paper Published

09:51 - 10:06  |  Author(s): Alex Adjei

WS03.10 - How to Give a Great Presentation

10:06 - 10:21  |  Author(s): Pasi A Janne

WS03.11 - Role of IASLC in Developing Countries

10:21 - 10:36  |  Author(s): Clarissa Mathias

WS03.12 - Early Career Researcher Experience

10:36 - 10:51  |  Author(s): Alessandro Russo

WS03.13 - Live Q&A

10:51 - 11:30

Session Moderator

PL01.08 - Welcome Address - IASLC CEO

WS08.05 - Minimal Residual Disease (MRD) Negative: Potential for Cure in Resected Oncogene Driven NSCLC? Chinese Perspective

21:10 - 21:30  |  Author(s): Jia-Tao Zhang

WS08.06 - Could MRD Change Our Clinical Practice? North American Perspective

21:30 - 21:50  |  Author(s): Aadel Chaudhuri

WS08.07 - How to Use Liquid Biopsy to Monitor Treatment Efficacy for Advanced Driven NSCLC

21:50 - 22:10  |  Author(s): Jie Hu

WS08.09 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer

22:30 - 22:40  |  Author(s): Si-Yang Maggie Liu

WS08.10 - Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study

22:40 - 22:50  |  Author(s): Baohui Han

WS08.13 - Activity of aPD1-MSLN-CART Cells Against Metastatic Lung Cancer in a Phase 1 Trial

23:20 - 23:21  |  Author(s): Lingjuan Chen

WS08.14 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-Negative NSCLC

23:21 - 23:22  |  Author(s): Lin Wu

WS08.15 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

23:22 - 23:23  |  Author(s): Jun Zhao

WS08.16 - The Increase of Blood Intratumor Heterogeneity is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC

23:23 - 23:24  |  Author(s): Juan Zhou

WS08.17 - Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer

23:24 - 23:25  |  Author(s): Peng Song

WS08.18 - Discussant for Poster 1 - 5

23:25 - 23:40  |  Author(s): Xiaorong Dong

WS08.24 - Discussant for Poster 6 - 10

23:35 - 23:50  |  Author(s): Ming Fang Zhao

WS08.19 - Phase Il Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer

23:40 - 23:41  |  Author(s): Yao-Bin Lin

WS08.20 - Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma

23:41 - 23:42  |  Author(s): Yuan Li

WS08.21 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer

23:42 - 23:43  |  Author(s): Wen-Fang Tang

WS08.22 - Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-arm, Phase 2 Trial (Renaissance Study)

23:43 - 23:44  |  Author(s): Shi Yan

WS08.23 - Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups

23:44 - 23:45  |  Author(s): LinPing Gu

EP08.01-061 - A Pilot Study of Avelumab and SABR in Non-Responding and Progressing NSCLC Patients Previously Treated with a Checkpoint Inhibitor

P2.12-03 - External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients With Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial